Janz S, Shacter E
Laboratory of Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cancer Biochem Biophys. 1995 Jun;15(1):25-34.
The intraperitoneal administration of pristane (2,6,10,14-tetramethylpentadecane) induces peritoneal plasmacytomas in genetically susceptible BALB/c mice. The purpose of this study was to estimate the disposition of an amount of intraperitoneally injected pristane that would conventionally be used in a tumor induction protocol. The distribution of 3H-labeled pristane in various tissues was monitored by liquid scintillation counting at different times after injection. The data show that pristane is present in the blood and detectable in all tested tissues during an observation period of one to 64 days. The levels of pristane fluctuate in some tissues such as lymph node and bone marrow but show a clear tendency to accumulate in others such as liver, spleen and kidney. Evidence is also presented for the in vivo metabolism of pristane based on the observed urinary excretion of tritium and on the high levels of radioactivity in the gall bladder fluid. It is concluded that intraperitoneally administered pristane is distributed throughout the mouse and is stored in tissues in sufficient amounts to allow interactions with the cells residing there.
腹腔注射降植烷（2,6,10,14 - 四甲基十五烷）可在基因易感的BALB/c小鼠中诱发腹腔浆细胞瘤。本研究的目的是评估在肿瘤诱导方案中常规使用的腹腔注射降植烷剂量的处置情况。在注射后不同时间通过液体闪烁计数监测3H标记降植烷在各种组织中的分布。数据表明，在1至64天的观察期内，降植烷存在于血液中且在所有测试组织中均可检测到。降植烷水平在某些组织如淋巴结和骨髓中波动，但在其他组织如肝脏、脾脏和肾脏中呈现明显的蓄积趋势。基于观察到的氚尿排泄以及胆囊液中的高放射性水平，也提供了降植烷体内代谢的证据。得出的结论是，腹腔注射的降植烷分布于整个小鼠体内，并以足够的量储存在组织中，以便与驻留在那里的细胞相互作用。
